Literature DB >> 6198448

Demonstration of neutralizing and non-neutralizing epitopes on the trypsin-sensitive site of foot-and-mouth disease virus.

E J Ouldridge, P V Barnett, N R Parry, A Syred, M Head, M M Rweyemamu.   

Abstract

The isolation of monoclonal antibodies directed against the trypsin-sensitive site on the 140S particle of foot-and-mouth disease virus (FMDV) has enabled the demonstration of at least three distinct epitopes within this site. Reaction with two of these resulted in neutralization of virus infectivity. None of the epitopes appeared to be present on the 12S particles, and one of the neutralizing epitopes was sensitive to even milder configurational changes of the particle.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198448     DOI: 10.1099/0022-1317-65-1-203

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells.

Authors:  M J Grubman; D O Morgan; J Kendall; B Baxt
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

2.  Characterization of monoclonal antibodies against a type SAT 2 foot-and-mouth disease virus.

Authors:  J R Crowther; C A Rowe; R Butcher
Journal:  Epidemiol Infect       Date:  1993-10       Impact factor: 2.451

3.  Immune response to uncoupled peptides of foot-and-mouth disease virus.

Authors:  M J Francis; C M Fry; D J Rowlands; J L Bittle; R A Houghten; R A Lerner; F Brown
Journal:  Immunology       Date:  1987-05       Impact factor: 7.397

4.  A high proportion of anti-peptide antibodies recognize foot-and-mouth disease virus particles.

Authors:  N R Parry; A Syred; D J Rowlands; F Brown
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

5.  Localization of a neutralization site of Theiler's murine encephalomyelitis viruses.

Authors:  S Nitayaphan; M M Toth; R P Roos
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.